<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">18191187</PMID>
<DateCompleted>
<Year>2008</Year>
<Month>03</Month>
<Day>20</Day>
</DateCompleted>
<DateRevised>
<Year>2019</Year>
<Month>05</Month>
<Day>08</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1095-6859</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>108</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2008</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>Gynecologic oncology</Title>
<ISOAbbreviation>Gynecol. Oncol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study.</ArticleTitle>
<Pagination>
<MedlinePgn>500-4</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ygyno.2007.11.017</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Topotecan 14-day infusion combined with cisplatin was highly active in ovarian cancer, but too myelosuppressive. We therefore sought to evaluate the feasibility of substituting oxaliplatin for cisplatin to improve safety.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Ovarian and primary peritoneal cancer patients, pretreated with at least one prior platinum-containing regimen, performance status (PS) 0-1, without prior pelvic radiation were eligible. Topotecan was continuously infused days 1-15; oxaliplatin was given days 1 and 15; cycles were repeated every 28 days. Five dose levels were explored: topotecan (mg/m2/day)/oxaliplatin (mg/m2) doses: (1) 0.2/65; (2) 0.2/75; (3) 0.2/85; (4) 0.3/85; (5) 0.4/85.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-three patients (20 ovarian, 1 tubal, and 2 peritoneal) were entered: median age 56 years (range, 37-77); PS: 0=12 and 1=11; histology: papillary serous 7, serous 4, adenocarcinoma 8, poorly differentiated 2. Median of 4 cycles were delivered. Grade 3 neutropenia occurred in 3 of 7 patients at level 5 (with fever at levels 4 and 5), without grade 4 neutropenia or thrombocytopenia. Other toxicities were mild and reversible (mainly gastrointestinal), except one grade 3 neuropathy and one oxaliplatin-related grade 3 hypersensitivity reaction. Six objective responses (five of them complete) were documented among 22 patients spanning several dose levels.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Topotecan continuous infusion, combined with oxaliplatin, was associated with no grade 4 hematologic toxicity and evidence of activity. The recommended phase II dose is topotecan 0.4 mg/m2/day continuous infusion d1-15 with oxaliplatin 85 mg/m2 on days 1 and 15. A phase II evaluation as second-line treatment for both platinum-sensitive and -resistant ovarian cancer recurrences is ongoing.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hochster</LastName>
<ForeName>Howard</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Division of Medical Oncology, New York University School of Medicine, NYU Cancer Institute, NY 10016, USA. howard.hochster@med.nyu.edu</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chen</LastName>
<ForeName>Thomas T</ForeName>
<Initials>TT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lu</LastName>
<ForeName>Janice M</ForeName>
<Initials>JM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hills</LastName>
<ForeName>Day</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sorich</LastName>
<ForeName>Joan</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Escalon</LastName>
<ForeName>Juliet</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ivy</LastName>
<ForeName>Percy</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Liebes</LastName>
<ForeName>Leonard</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Muggia</LastName>
<ForeName>Franco</ForeName>
<Initials>F</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P30 CA016087</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U10 CA021115</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U01 CA076642-05</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U01 CA076642</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>N01 CM062204</GrantID>
<Acronym>CM</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U01 CA076642-03</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA76642</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>N01 CM007003</GrantID>
<Acronym>CM</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA16087</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>U01 CA076642-04</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>N01-CM-07003-74S</GrantID>
<Acronym>CM</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA21115(-27)</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2008</Year>
<Month>01</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Gynecol Oncol</MedlineTA>
<NlmUniqueID>0365304</NlmUniqueID>
<ISSNLinking>0090-8258</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009944">Organoplatinum Compounds</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>04ZR38536J</RegistryNumber>
<NameOfSubstance UI="D000077150">Oxaliplatin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7M7YKX2N15</RegistryNumber>
<NameOfSubstance UI="D019772">Topotecan</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000230">Adenocarcinoma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000231">Adenocarcinoma, Papillary</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018284">Cystadenocarcinoma, Serous</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004334">Drug Administration Schedule</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007262">Infusions, Intravenous</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009367">Neoplasm Staging</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009944">Organoplatinum Compounds</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010051">Ovarian Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000077150">Oxaliplatin</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010534">Peritoneal Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019772">Topotecan</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2007</Year>
<Month>08</Month>
<Day>13</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised">
<Year>2007</Year>
<Month>11</Month>
<Day>05</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2007</Year>
<Month>11</Month>
<Day>19</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2008</Year>
<Month>1</Month>
<Day>15</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2008</Year>
<Month>3</Month>
<Day>21</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2008</Year>
<Month>1</Month>
<Day>15</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">18191187</ArticleId>
<ArticleId IdType="pii">S0090-8258(07)00929-8</ArticleId>
<ArticleId IdType="doi">10.1016/j.ygyno.2007.11.017</ArticleId>
<ArticleId IdType="pmc">PMC3572735</ArticleId>
<ArticleId IdType="mid">NIHMS42700</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>J Clin Oncol. 1999 Aug;17(8):2553-61</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10561322</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Gynecol Oncol. 2007 Feb;104(2):422-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16996118</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2001 Jul 15;19(14):3312-22</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11454878</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Oncol. 2002 Mar;13(3):399-402</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11996470</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Cancer. 2002 Sep;38(14):1888-98</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12204671</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Oncol. 2004 Jan;15(1):100-3</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14679127</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer. 2004 Jan 1;100(1):211-2</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14692042</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Chemother Pharmacol. 2004 Aug;54(2):178-84</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15114411</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biomed Pharmacother. 1989;43(4):237-50</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2675999</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Pharm Biomed Anal. 1990;8(8-12):789-94</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2100624</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 1992 Apr;10(4):513-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1548513</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Natl Cancer Inst. 1996 Jun 5;88(11):734-41</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8637027</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochem Pharmacol. 1996 Dec 24;52(12):1855-65</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8951344</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 1996 Dec;14(12):3056-61</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8955650</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 1996 Dec;14(12):3074-84</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8955652</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Oncol. 1996 Dec;7(10):1065-70</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9037366</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 1997 May 15;57(10):1841-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9157971</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Cancer. 1997 Aug;33(9):1400-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9337681</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 1998 Mar;4(3):545-57</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9533521</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 1997 Aug;3(8):1245-52</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9815806</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2005 Aug 15;11(16):5912-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16115933</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Gynecol Oncol. 2006 Feb;100(2):324-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16253316</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncologist. 2006 May;11(5):529-31; author reply 531-2</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16720854</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Gynecol Oncol. 2006 Nov;103(2):473-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16631245</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2000 Mar;18(6):1193-202</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10715288</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>